Press release
VESTAKEEP for Implants
June 10, 2021

New 3D-printable PEEK Care Filament for more individualization in medical technology   

With VESTAKEEP® Care M40 3DF, Evonik is launching a polyether ether ketone filament for medical applications with body contact up to 30 days.

  • VESTAKEEP® Care M40 3DF for medical applications with body contact up to 30 days
  • New possibilities in the individual treatment of patients
  • Further filaments for additive manufacturing in the pipeline

Shanghai/Darmstadt. Evonik has developed a new 3D-printable PEEK biomaterial for medical technology. With VESTAKEEP® Care M40 3DF, the specialty chemicals company is launching a polyether ether ketone filament for medical applications with body contact up to 30 days. The high-performance polymer can be processed in common extrusion-based 3D printing technologies such as fused filament fabrication (FFF) or fused deposition modeling (FDM). With the product launch, Evonik is expanding the possibilities for individual treatment of patients using additive manufacturing.     

Biomaterials for individual patient treatment

The new PEEK filament is the latest addition to Evonik’s "Care Grade" line based on the high-performance polymer VESTAKEEP® Care M40. The product impresses with its biocompatibility, excellent temperature and chemical resistance, very good sterilizability, and easy handling. The range of possible applications extends from patient-specific hearing aids to filigree prostheses and orthoses to surgical drilling aids for dentistry or individual surgical instruments.  

With a diameter of 1.75 mm, VESTAKEEP® Care M40 3DF is supplied in natural color on 500-gram spools that can be used directly in standard FFF/FDM 3D printers for PEEK materials. The filament is manufactured under cleanroom conditions and then subjected to strict quality management for medical materials. 

Revolutionizing medical technology

"Following the commercial success of our VESTAKEEP® i4 3DF filament for 3D printing long-term permanent implants, we are now expanding the possibilities of modern medical technology for the individual treatment of patients with this new Care product," says Marc Knebel, head of the Medical Devices & Systems market segment at Evonik. "In order to open up further medical applications for even better quality of life, a broad material landscape is needed. We have our fingers on the pulse with our portfolio of 3D biomaterials and are consistently developing it further. Doing so, this year we plan to launch an innovative PEEK-based filament with osteoconductive properties allowing bone cells to adhere to implants more quickly. Our goal is to revolutionize medical technology by offering innovative material solutions."

For more than 20 years, Evonik has been the world’s leading manufacturer of high-performance polymers and additives used in additive manufacturing. The specialty chemicals company offers the industry’s most extensive portfolio of GMP-grade biomaterials used in the 3D printing of medical device parts designed for temporary and permanent body contact. In addition to VESTAKEEP® i4 3DF and VESTAKEEP® Care M40 3DF, the portfolio includes the RESOMER® line of bioresorbable filaments, powders and granules for implantable medical devices.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Smart Materials

The Smart Materials division includes businesses with innovative materials that enable resource-saving solutions and replace conventional materials. They are the smart answer to the major challenges of our time: environment, energy efficiency, urbanization, mobility and health. The Smart Materials division generated sales of €3.24 billion in 2020 with about 7,900 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.